T1	p 93 132	advanced epithelial ovarian carcinoma .
T2	p 296 403	patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen . PATIENTS
T3	p 416 464	Patients with bidimensionally measurable disease
T4	p 982 1033	total of 226 patients were evaluable for response .
T5	i 62 89	topotecan versus paclitaxel
T6	i 265 292	topotecan versus paclitaxel
T7	i 484 600	topotecan ( 1.5 mg/m ( 2 ) /day for 5 days ) or paclitaxel ( 175 mg/m ( 2 ) /day as a 3-h infusion ) every 21 days .
T8	i 647 664	alternate therapy
T9	i 1162 1171	topotecan
T10	i 1279 1289	paclitaxel
T11	i 1420 1429	topotecan
T12	i 1509 1519	paclitaxel
T13	i 1676 1686	paclitaxel
T14	i 1920 1929	topotecan
T15	o 685 706	European Organisation
T16	o 724 792	Treatment of Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire
T17	o 870 971	pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .
T18	o 1125 1153	EORTC QOL-30 questionnaire .
T19	o 1180 1206	median time to progression
T20	o 1397 1412	median survival
T21	o 1651 1672	efficacy and survival
T22	o 1707 1775	non-cumulative haematological toxicity . Non-haematological toxicity
T23	o 1817 1840	long-term survival rate